Inavolisib (Itovebi) is a new targeted therapy for HR+ HER2-negative metastatic breast cancer with a PIK3CA mutation.

Ulipristal can inhibit follicular rupture when administered ... of 19-norprogesterone that functions as a selective progesterone receptor modulator (SPRM) with both agonistic and antagonistic ...

Dr. Mabel Mardones educates patients on breast cancer subtypes, as well as treatment options for those with ER-positive, HER2 ...

This physical interaction results in mutual inhibition of transcriptional ... which is used therapeutically to antagonize the progesterone receptor to induce abortion but also antagonizes the ...

Estrogen and progesterone combined in OCs act in a ... thereby inhibiting ovulation. Gonadotropin inhibition also has the effect of reducing the androgen production of ovarian theca cells and ...

Consistent with this dichotomy, there is good evidence that Eph receptors and ephrins can both promote and inhibit tumorigenicity. The factors responsible for these divergent activities are only ...

ASCO Data Shows New Therapy Delays Breast Cancer Progression and May Improve Quality of Life for Women with Hormone Receptor-Positive Disease.

Emerging research continues to spotlight the potential role of diet in cancer prevention, with olive oil—a cornerstone of the Mediterranean diet&mdas | Drug Discovery And Development ...

Men lose more weight than women on a ketogenic diet, according to a comprehensive review in Frontiers in Nutrition. Sex ...

Darolutamide is the first and only in the U.S. and FDA-approved androgen receptor inhibitor (ARi) for the treatment of patients with hormone-sensitive prostate cancer (mHSPC), in combination with ...